Summary
Guardant Health, Inc. (GH) reported its first-quarter 2022 financial results, demonstrating continued revenue growth driven by its precision oncology testing business. Total revenue increased by 22% year-over-year to $96.1 million, with precision oncology testing revenue up 32% to $84.1 million. This growth was fueled by a significant increase in test volumes for both clinical and biopharmaceutical customers. Despite the revenue expansion, the company continued to operate at a loss, reporting a net loss of $123.2 million for the quarter. However, the company maintains a strong liquidity position, with cash, cash equivalents, and marketable securities totaling approximately $1.6 billion as of March 31, 2022. The company highlighted strategic advancements, including regulatory approvals and new product launches. Guardant360 CDx received important regulatory approvals in Japan, expanding its international reach. The launch of the Shield LDT blood test for early colorectal cancer detection in May 2022 and the ongoing development of its investigational multi-cancer assay Guardant SHIELD indicate a commitment to early cancer detection. While operating expenses, particularly in research and development and sales and marketing, saw significant increases to support these initiatives, the company believes its current financial resources are sufficient to fund its operating plan for at least the next twelve months. Investors should closely monitor the company's ability to control escalating operating expenses and its progress in achieving broader reimbursement and adoption for its expanding diagnostic portfolio.
Financial Highlights
50 data points| Revenue | $96.10M |
| R&D Expenses | $81.76M |
| Operating Expenses | $219.44M |
| Operating Income | -$123.34M |
| Interest Expense | $644K |
| Net Income | -$123.23M |
| EPS (Basic) | $-1.21 |
| EPS (Diluted) | $-1.21 |
| Shares Outstanding (Basic) | 101.85M |
| Shares Outstanding (Diluted) | 101.85M |
Key Highlights
- 1Total revenue grew 22% to $96.1 million in Q1 2022, driven by a 32% increase in precision oncology testing revenue to $84.1 million.
- 2Precision oncology testing revenue from clinical customers increased by 32% to $66.0 million, supported by higher test volumes and improved average selling prices due to ADLT status for Guardant360 CDx.
- 3The company reported a net loss of $123.2 million for the quarter, consistent with its investment-focused growth strategy.
- 4Guardant Health maintained a strong liquidity position with $1.6 billion in cash, cash equivalents, and marketable securities as of March 31, 2022.
- 5Significant investments were made in research and development (+47%) and sales and marketing (+88%) to support new product launches, clinical studies, and market expansion.
- 6The company launched the Shield LDT blood test for early colorectal cancer detection in May 2022.
- 7Guardant360 CDx received key regulatory approvals in Japan, supporting international expansion efforts.